Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Compass Therapeutics, Inc. presented promising preclinical data on CTX-471, a CD137 agonist antibody, at the AACR Annual Meeting, indicating enhanced efficacy in models of immune checkpoint failure through simultaneous blockade of neo-angiogenesis [1][2][3] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology, with a scientific emphasis on the interplay between angiogenesis, the immune system, and tumor growth [10] Product Development - CTX-471 is currently in a Phase 1b clinical trial for patients with solid tumors that have progressed after at least three months on approved PD-1 or PD-L1 inhibitors, showing partial responses in melanoma, small cell lung cancer, and mesothelioma [5] - The combination of CTX-471 with tovecimig has demonstrated significant anti-tumor efficacy in murine models resistant to conventional immune checkpoint inhibitors, suggesting a potential therapeutic regimen for patients who have failed checkpoint inhibitors [7][9] Mechanism of Action - The combination therapy appears to enhance innate and adaptive anti-tumor immunity, including increased tumor cell killing and interferon signaling, which may provide clinical benefits for patients previously unresponsive to standard treatments [3][7] Ongoing Trials - The ongoing COMPANION-002 trial is evaluating the efficacy of tovecimig in combination with paclitaxel for patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers [9]